ClinicalTrials.gg
CompletedNCT05970315Updated Nov 13, 2026Results posted

Priorities Aligned Deprescribing for Persons Living With Dementia and Their Caregiver

An interventional study of PPC and Usual care in Dementia, sponsored by The University of Texas Health Science Center, Houston. Completed at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 13, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Non-randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,051 studies in Dementia with a site in United States — 211 open to participants now, 276 under way, 15 of them phase 3. Dementia · United States.

Enrollment
410th of 846
98 · median 93
Started
2023
with 86 others
No phase
562 of 1,051
118 open now
Registered
821st of 1,051
by date

Among the 1,051 studies in Dementia with a site in United States, this one is the 410th largest by enrollment of the 846 interventional ones that give a count, is one of 87 that started in 2023, is one of 562 with no phase, and was the 821st registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

211 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,051 studies in Dementia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare patient priorities care (PPC) and usual care (UC) patients to identify differences in post-encounter medication changes, treatment burden (TBQ), and shared decision making in Older Patient Assessment of Chronic Illness Care (OPACIC), to understand PPC participant's sense-making and communication approaches related to deprescribing decisions in relation to the identified health priorities and to identify and categorize adverse drug withdrawal events (ADWEs)

03

Conditions studied

  • Dementia

Browse trials for

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dementia listed as an active problem in the medical record, including Alzheimer's disease, vascular dementia, frontotemporal dementia, Parkinson's dementia, Lewy body disease.
  • The functional assessment staging tool (FAST) score of 5 or lower (This will be established by the patient's clinician).
  • 2 or more additional chronic conditions
  • Takes 5 or more regular medications and
  • A caregiver present during visits. Caregivers may include family members or unrelated caregivers and will be identified through chart review and confirmed by clinician, patient, and surrogate decision maker if necessary. Identified caregivers must be involved in decisions and care of People living with dementia (PLWD) and routinely attend clinic visits with patient

Exclusion criteria

Exclusion Criteria:

  • FAST score of 6 or more (This will be established by the patient's clinician).
  • Significant hearing, vision, or advanced cognitive impairment that limits ability to participate in PPC encounters,
  • Caregiver is unwilling or able to participate in visits, or
  • Deemed ineligible by their Primary care physician (PCP)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    PPC

    Behavioral: PPC

  • Active comparator
    Usual Care

    Behavioral: Usual care

Interventions

  • BehavioralPPC

    Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities.

  • BehavioralUsual care

    Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden.

06

What researchers measure

Primary outcomes

  1. Total Number of Medication Changes

    Total Number of medication changes that happened between baseline and three month follow up among Dementia Participants.

    Time frame: Baseline, 3 month

  2. Type of Medication Changes

    Medication changes corresponding to the type of changes among Dementia Participants: added or increased, discontinued or decreased, avoided.

    Time frame: Baseline, 3 month

  3. Number of Participants by Change in Patient Report Treatment Burden as Assessed by the Treatment Burden Questionnaire (TBQ)

    The questionnaire consists of 15 items, each scored on a scale from 0 (not a problem) to 10 (a very big problem), yielding a total score range of 0 to 150, with higher scores indicating greater treatment burden. TBQ total scores were assessed at baseline and at 3 months. Change in treatment burden was calculated by subtracting the baseline total TBQ score from the 3-month TBQ score (3 month minus baseline). Participants were categorized based on change in score as follows: * reduced burden (change score \< 0) * no change in burden (change score = 0) * increased burden (change score \> 0)

    Time frame: Baseline, 3 month

  4. Number of Participants by Likelihood of Adverse Drug Reactions (ADRs) as Assessed by the Naranjo Scale

    Naranjo scale is a questionnaire used to assess the likelihood that an adverse event is related to a drug. Total scores range from -4 to +13. Adverse drug reactions were categorized based on total score as follows: * Definite (≥ 9): Reaction followed a reasonable temporal sequence after drug exposure, matched a recognized drug response, improved after withdrawal, and recurred upon re-exposure. * Probable (5 to 8): Reaction followed drug exposure, matched a recognized drug response, improved after withdrawal, and was not reasonably explained by the patient's clinical condition. * Possible (1 to 4): Reaction followed drug exposure and may fit a recognized drug response but could also be explained by the underlying disease or other factors. * Doubtful (≤ 0): The reaction was due to factors other than a drug. * No Adverse Reaction: Participants who did not experience any adverse reactions. The Naranjo Scale was not administered because there was no suspected reaction to evaluate.

    Time frame: 3 months

  5. Number of Participants by Adverse Drug Withdrawal Events (ADWEs) as Assessed by the Naranjo Scale

    The Naranjo Scale assesses the likelihood that an adverse event is related to a drug withdrawal. Total scores range from -4 to +13. Adverse drug withdrawal events (ADWEs) were categorized as follows: * Definite (≥ 9): Withdrawal reaction followed drug discontinuation, matched a recognized withdrawal syndrome, improved with treatment or re-exposure, and recurred after subsequent discontinuation * Probable (5 to 8): Withdrawal reaction followed drug discontinuation, matched a recognized withdrawal syndrome, improved with management or re-exposure, and could not be explained by the patient's condition * Possible (1 to 4): Withdrawal reaction followed drug discontinuation and may fit a recognized withdrawal syndrome but could also be explained by an underlying disease or other factors. * Doubtful (≤ 0): Withdrawal reaction likely due to factors other than drug discontinuation * No Withdrawal Reaction: No suspected adverse drug withdrawal event. The Naranjo Scale was not administered

    Time frame: 3 months

Secondary outcomes

  1. Change in Patient Perceived Chronic Disease Care as Assessed by the Older Patient Assessment of Chronic Illness Care (OPACIC) Score

    The Older Patient Assessment of Chronic Illness Care (OPACIC) score ranges from 10 to 50, with higher scores indicating better perceived chronic disease care. The change in score is reported as \[(OPACIC score at 3 months) - (OPACIC score at baseline)\]--a positive value indicates improvement in perceived chronic disease care over time.

    Time frame: Baseline, 3 months

07

Results

Posted Nov 13, 2026
Limitations and caveats
* Due to concerns for contamination, we used a quasi-experimental design. We conducted control arm first, and then intervention * Due to change in study design and early staff turnover, we experienced higher than desired rate of missing data in main outcome measures

Participant flow

Participant flow — Overall Study
MilestonePatient Priorities Care: Intervention GroupUsual Care: Control Group
Started6830
Completed6430
Not completed40

Outcome measures

PrimaryTotal Number of Medication Changes

Total Number of medication changes that happened between baseline and three month follow up among Dementia Participants.

Time frame:
Baseline, 3 month
Reported as:
Number · Number of Medication Changes
Total Number of Medication Changes
Number of Medication ChangesPatient Priorities Care: Intervention GroupUsual Care: Control Group
Total Number of Medication Changes2414
PrimaryType of Medication Changes

Medication changes corresponding to the type of changes among Dementia Participants: added or increased, discontinued or decreased, avoided.

Time frame:
Baseline, 3 month
Reported as:
Number · Number of Medication changes
Type of Medication Changes
Number of Medication changesPatient Priorities Care: Intervention GroupUsual Care: Control Group
Medications added or increased167
Medications avoided25
Medications discontinued or decreased62
PrimaryNumber of Participants by Change in Patient Report Treatment Burden as Assessed by the Treatment Burden Questionnaire (TBQ)

The questionnaire consists of 15 items, each scored on a scale from 0 (not a problem) to 10 (a very big problem), yielding a total score range of 0 to 150, with higher scores indicating greater treatment burden. TBQ total scores were assessed at baseline and at 3 months. Change in treatment burden was calculated by subtracting the baseline total TBQ score from the 3-month TBQ score (3 month minus baseline). Participants were categorized based on change in score as follows: * reduced burden (change score \< 0) * no change in burden (change score = 0) * increased burden (change score \> 0)

Time frame:
Baseline, 3 month
Reported as:
Count of participants · Participants
Number of Participants by Change in Patient Report Treatment Burden as Assessed by the Treatment Burden Questionnaire (TBQ)
ParticipantsPatient Priorities Care: Intervention GroupUsual Care: Control Group
Reduced burden (change score < 0)67
No change in burden (change score = 0)01
Increased burden (change score > 0).161
PrimaryNumber of Participants by Likelihood of Adverse Drug Reactions (ADRs) as Assessed by the Naranjo Scale

Naranjo scale is a questionnaire used to assess the likelihood that an adverse event is related to a drug. Total scores range from -4 to +13. Adverse drug reactions were categorized based on total score as follows: * Definite (≥ 9): Reaction followed a reasonable temporal sequence after drug exposure, matched a recognized drug response, improved after withdrawal, and recurred upon re-exposure. * Probable (5 to 8): Reaction followed drug exposure, matched a recognized drug response, improved after withdrawal, and was not reasonably explained by the patient's clinical condition. * Possible (1 to 4): Reaction followed drug exposure and may fit a recognized drug response but could also be explained by the underlying disease or other factors. * Doubtful (≤ 0): The reaction was due to factors other than a drug. * No Adverse Reaction: Participants who did not experience any adverse reactions. The Naranjo Scale was not administered because there was no suspected reaction to evaluate.

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Participants by Likelihood of Adverse Drug Reactions (ADRs) as Assessed by the Naranjo Scale
ParticipantsPatient Priorities Care: Intervention Group
Definite (Score is 9 or higher)0
Probable (Score is 5 to 8)0
Possible (Score is 1 to 4)3
Doubtful (-4 to 0)0
No Adverse Reaction27
PrimaryNumber of Participants by Adverse Drug Withdrawal Events (ADWEs) as Assessed by the Naranjo Scale

The Naranjo Scale assesses the likelihood that an adverse event is related to a drug withdrawal. Total scores range from -4 to +13. Adverse drug withdrawal events (ADWEs) were categorized as follows: * Definite (≥ 9): Withdrawal reaction followed drug discontinuation, matched a recognized withdrawal syndrome, improved with treatment or re-exposure, and recurred after subsequent discontinuation * Probable (5 to 8): Withdrawal reaction followed drug discontinuation, matched a recognized withdrawal syndrome, improved with management or re-exposure, and could not be explained by the patient's condition * Possible (1 to 4): Withdrawal reaction followed drug discontinuation and may fit a recognized withdrawal syndrome but could also be explained by an underlying disease or other factors. * Doubtful (≤ 0): Withdrawal reaction likely due to factors other than drug discontinuation * No Withdrawal Reaction: No suspected adverse drug withdrawal event. The Naranjo Scale was not administered

Time frame:
3 months
Reported as:
Count of participants · Participants
Number of Participants by Adverse Drug Withdrawal Events (ADWEs) as Assessed by the Naranjo Scale
ParticipantsPatient Priorities Care: Intervention Group
Definite (Score is 9 or higher)0
Probable (Score is 5 to 8)0
Possible (Score is 1 to 4)0
Doubtful (Score is -4 to 0)0
No withdrawal reaction30
SecondaryChange in Patient Perceived Chronic Disease Care as Assessed by the Older Patient Assessment of Chronic Illness Care (OPACIC) Score

The Older Patient Assessment of Chronic Illness Care (OPACIC) score ranges from 10 to 50, with higher scores indicating better perceived chronic disease care. The change in score is reported as \[(OPACIC score at 3 months) - (OPACIC score at baseline)\]--a positive value indicates improvement in perceived chronic disease care over time.

Time frame:
Baseline, 3 months
Reported as:
Mean · score on a scale
Change in Patient Perceived Chronic Disease Care as Assessed by the Older Patient Assessment of Chronic Illness Care (OPACIC) Score
score on a scalePatient Priorities Care: Intervention GroupUsual Care: Control Group
Change in Patient Perceived Chronic Disease Care as Assessed by the Older Patient Assessment of Chronic Illness Care (OPACIC) Score1.72 ± 8.70.5 ± 14.05

Adverse events

Collected over Up to 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patient Priorities Care: Intervention Group0/34 (0%)0/34 (0%)3/34 (8.8%)
Usual Care : Control Group0/15 (0%)0/15 (0%)0/15 (0%)
Most frequent other events
Most frequent other events
EventPatient Priorities Care: Intervention GroupUsual Care : Control Group
Sleep disorderGeneral disorders1/340/15
Urinary IncontinenceRenal and urinary disorders1/340/15
Edema in legsGeneral disorders1/340/15

Baseline characteristics

Baseline characteristics data includes all participants who completed the study

Age, Continuous
Age, Continuous(Years)Patient Priorities Care: Intervention GroupUsual Care : Control GroupTotal
Dementia Participant84.39 ± 7.8082.13 ± 6.5983.38 ± 7.21
Caregiver61.13 ± 11.5865.00 ± 11.4262.27 ± 11.54
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Patient Priorities Care: Intervention GroupUsual Care : Control GroupTotal
Dementia Participant — Female221133
Dementia Participant — Male10414
Dementia Participant — Not Reported000
Caregiver — Female26935
Caregiver — Male5611
Caregiver — Not Reported101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Patient Priorities Care: Intervention GroupUsual Care : Control GroupTotal
Dementia Participant — Hispanic or Latino426
Dementia Participant — Not Hispanic or Latino281341
Dementia Participant — Unknown or Not Reported000
Caregiver — Hispanic or Latino426
Caregiver — Not Hispanic or Latino261238
Caregiver — Unknown or Not Reported213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Patient Priorities Care: Intervention GroupUsual Care : Control GroupTotal
Dementia Participant — White16824
Dementia Participant — Black or African American12517
Dementia Participant — Other325
Dementia Participant — Not reported101
Dementia Participant — More than One Race000
Dementia Participant — American Indian or Alaska Native000
Dementia Participant — Asian000
Dementia Participant — Native Hawaiian or Other Pacific Islande000
Caregiver — White16824
Caregiver — Black or African American10414
Caregiver — Other404
Caregiver — Not reported224
Caregiver — More than One Race011
Caregiver — American Indian or Alaska Native000
Caregiver — Asian000
Caregiver — Native Hawaiian or Other Pacific Islande000
Region of Enrollment
Region of Enrollment(participants)Patient Priorities Care: Intervention GroupUsual Care : Control GroupTotal
United States643094
08

Study locations

1 site
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jun 2025, 23 months.

Results were first posted in Nov 2026, 1 year 4 months after primary completion.

Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 23 months is close to that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 1, 2023
StartActual
Jul 6, 2023
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Enrollment
45→98
Nov 13, 2026
Primary outcomes
5 edited
What changed in the outcomes
  • EditedTotal Number of medication changesMedication ChangesTime frame: Baseline, 3 month
  • EditedType of medication changesMedication ChangesTime frame: Baseline, 3 month
  • EditedNumber of Participants by Change in patient reported treatment burdenPatient Report Treatment Burden as assessedAssessed by the Treatment Burden Questionnaire (TBQ)Time frame: Baseline, 3 month
  • EditedNumber, likelihood, and severity of adverse drug reactionsParticipants by Likelihood of Adverse Drug Reactions (ADRs) as assessedAssessed by the Naranjo scaleScaleTime frame: 3 months
  • EditedNumber, likelihood, and severity of adverse drug withdrawal eventsParticipants by Adverse Drug Withdrawal Events (ADWEs) as assessedAssessed by the Naranjo scaleScaleTime frame: 3 months
Nov 13, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChange in Patient perceived chronic disease carePerceived Chronic Disease Care as assessedAssessed by the Older Patient Assessment of Chronic Illness Care (OPACIC) scoreScoreTime frame: Baseline, 3 months
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Results posted
    Enrollment 45→98
    Primary outcomes 5 edited
    What changed in the outcomes
    • EditedTotal Number of medication changesMedication ChangesTime frame: Baseline, 3 month
    • EditedType of medication changesMedication ChangesTime frame: Baseline, 3 month
    • EditedNumber of Participants by Change in patient reported treatment burdenPatient Report Treatment Burden as assessedAssessed by the Treatment Burden Questionnaire (TBQ)Time frame: Baseline, 3 month
    • EditedNumber, likelihood, and severity of adverse drug reactionsParticipants by Likelihood of Adverse Drug Reactions (ADRs) as assessedAssessed by the Naranjo scaleScaleTime frame: 3 months
    • EditedNumber, likelihood, and severity of adverse drug withdrawal eventsParticipants by Adverse Drug Withdrawal Events (ADWEs) as assessedAssessed by the Naranjo scaleScaleTime frame: 3 months
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in Patient perceived chronic disease carePerceived Chronic Disease Care as assessedAssessed by the Older Patient Assessment of Chronic Illness Care (OPACIC) scoreScoreTime frame: Baseline, 3 months
    + 3 other changes: index terms, verification date and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05970315
Responsible party
Aanand Dinkar Naik (Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Aug 1, 2023
Start date
Jul 6, 2023
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Study contacts

Aanand D Naik, MD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion